Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Analyzing genes that are present in cancer cells may be useful as a method for
predicting the response of non-Hodgkin's lymphoma to cancer treatment. Imaging procedures
such as positron emission tomography (PET) scans may improve the ability to measure how well
cancer has responded to treatment.
PURPOSE: This phase II trial is studying molecular risk assessment to see how well it works
in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's
lymphoma.